Form 4: Glaukos Corp SVP Alex R. Thurman Sells Shares Under 10b5-1 Trading Plan

Alex R. Thurman, SVP & CFO of Glaukos Corporation, sold a portion of his holdings in common stock on April 3rd and 4th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Alex R. Thurman, the SVP & CFO of Glaukos Corporation, reported the sale of common stock on April 3rd and 4th, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 17, 2023.
• On April 3, 2024, 316 shares were sold at a price of $94.62 per share.
• On April 4, 2024, two transactions occurred: 276 shares were sold at a weighted average price of $95.42, and 158 shares were sold at a weighted average price of $95.16.
• Following these transactions, Thurman beneficially owns 54,166 shares of Glaukos Corp common stock, which includes 22,898 restricted stock units that have not yet vested.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The stock sales were conducted under a pre-arranged 10b5-1 trading plan, which suggests they were planned for personal financial reasons and not necessarily indicative of a negative outlook on the company. However, any insider selling can be perceived negatively by some investors.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Negatives

• The sale of shares by a high-ranking officer could be perceived negatively by some investors, although the 10b5-1 plan mitigates this concern.

Risks

• While the 10b5-1 plan provides a framework for pre-planned sales, continued selling activity by insiders could create downward pressure on the stock price.

Industry Context

Insider trading activity is always closely watched in the pharmaceutical and medical device industries, as it can provide insights into management's perspective on the company's future prospects. However, sales under 10b5-1 plans are common and often pre-scheduled for personal financial planning.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, including those in the medical device sector like Alcon or Johnson & Johnson's vision care division, to utilize 10b5-1 trading plans for managing their stock holdings.
• The size and frequency of these transactions are generally in line with what is observed among peer companies, where executives periodically sell shares for diversification or liquidity purposes.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they interpret the sales negatively, although the existence of the 10b5-1 plan should mitigate concerns.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates